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Abstract
Background: Toll-like receptor 4 (TLR4), the signaling receptor for lipopolysaccharides, is an important
member of the innate immunity system. Since several studies have suggested that type 2 diabetes might be
associated with changes in the innate immune response, we sought to investigate the association between
genetic variants in the TLR4 gene and incident type 2 diabetes.
Methods:  A case-cohort study was conducted in initially healthy, middle-aged subjects from the
MONICA/KORA Augsburg studies including 498 individuals with incident type 2 diabetes and 1,569 non-
cases. Seven SNPs were systematically selected in the TLR4 gene and haplotypes were reconstructed.
Results: The effect of TLR4 SNPs on incident type 2 diabetes was modified by the ratio of total cholesterol
to high-density lipoprotein cholesterol (TC/HDL-C). In men, four out of seven TLR4 variants showed
significant interaction with TC/HDL-C after correction for multiple testing (p < 0.01). The influence of the
minor alleles of those variants on the incidence of type 2 diabetes was observed particularly for male
patients with high values of TC/HDL-C. Consistent with these findings, haplotype-based analyses also
revealed that the effect of two haplotypes on incident type 2 diabetes was modified by TC/HDL-C in men
(p < 10-3). However, none of the investigated variants or haplotypes was associated with type 2 diabetes
in main effect models without assessment of effect modifications.
Conclusion: We conclude that minor alleles of several TLR4 variants, although not directly associated
with type 2 diabetes might increase the risk for type 2 diabetes in subjects with high TC/HDL-C.
Additionally, our results confirm previous studies reporting sex-related dissimilarities in the development
of type 2 diabetes.
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Background
Subclinical, low-grade systemic inflammation has been
implicated in the pathogenesis and prediction of type 2
diabetes. Several studies have shown that elevated levels
of inflammatory and endothelial cell markers predict dia-
betes [1]. Both animal models and studies in humans
have suggested that type 2 diabetes might be associated
with changes in the innate immune response [1-3].
Toll-like receptors are members of the interleukin 1 recep-
tor family, an evolutionary conserved signalling system
against invading pathogens [4]. Due to their ability to rec-
ognize microbial components, mammalian toll-like
receptors are among the most important components of
the innate immunity pathway [5]. The first described and
best-known member of this family is TLR4, identified as
the signaling receptor for lipopolysaccharides [6]. TLR4
also interacts with endogenous ligands such as heat shock
proteins [7], fibronectin, fibrinogen [8], minimally mod-
ified and oxidized low-density lipoprotein (LDL) [9,10]
and free fatty acids [11], which are elevated in diabetes
[12-14]. TLR4 ligation activates several intracellular sig-
nalling pathways, with TLR4/nuclear factor κB pathway
being the most important one [15], leading to the synthe-
sis and release of inflammatory cytokines and other cos-
timulatory molecules that provide a link to adaptive
immunity [16].
To date several single nucleotide polymorphisms (SNPs)
have been identified in the TLR4 gene. Two of them, the
congregated Asp299Gly and the Thr399Ile have been
intensively studied and the rare allele 299Gly has been
shown to cause hyporesponsiveness to lipopolysaccha-
rides [17] and was reported to be associated with reduced
incidence of carotid plaques and slowing progression of
carotid atherosclerosis, as measured by carotid artery
intima-media thickness [18].
Human genetic association studies of the TLR4  gene
include only few that have assessed the relationship
between genotype and type 2 diabetes and its complica-
tions and most of these studies have been restricted to
those two polymorphisms, without consideration of the
patterns of variation across the locus as a whole. Since a
chronic low-grade inflammation seen in type 2 diabetes
and in atherosclerosis may be related to common genetic
predisposition and environmental risk factors, modula-
tion of the systemic immune balance through gene poly-
morphisms might play a crucial role. Moreover, to our
knowledge, there are no published prospective data eval-
uating the association between TLR4  variants and the
development of type 2 diabetes. Therefore, we sought to
systematically investigate the gender-specific association
between genetic variants in the gene coding for the TLR4
receptor and incident type 2 diabetes in a prospective pop-
ulation-based case-cohort study. In addition, given that
TLR4 has been reported to bind LDL [9,10], we wanted to
analyze whether cholesterol levels have an effect on this
association.
Methods
Study design
We designed a prospective case-cohort study within the
population-based Monitoring of Trends and Determi-
nants in Cardiovascular Disease (MONICA)/Cooperative
Health Research in the Augsburg Region (KORA) Augs-
burg cohort study (1984–2002) [19]. As part of the inter-
national WHO MONICA project, three independent
cross-sectional population-based studies (surveys) cover-
ing the city of Augsburg (Germany) and two adjacent
counties were conducted in 1984/85 (S1), 1989/90 (S2)
and 1994/95 (S3) to estimate the prevalence and distribu-
tion of cardiovascular risk factors among individuals aged
25 to 64 (S1) or 25 to 74 years (S2, S3). The study com-
plies with the declaration of Helsinki. Approval was
obtained by local ethic committees and informed consent
was given from all patients. The total number of partici-
pants was 13,427 (6,725 men and 6,702 women). All sub-
jects were prospectively followed within the framework of
the MONICA/KORA studies [20]. The present study was
restricted to subjects aged 35 to 74 years at baseline, since
the incidence of type 2 diabetes is low in younger subjects.
Altogether 10,718 persons (5,382 men and 5,336
women) of this age range participated in at least one of the
three baseline surveys. After exclusion of 1,187 subjects
with missing blood samples and 1,595 participants with
prevalent type 2 diabetes, incident diabetes other than
type 2 diabetes (e.g. type 1 or secondary diabetes), with
self-reported, but not validated incident type 2 diabetes,
without follow-up information or with a follow-up time
of <1 year, the source population for the present study
comprised 7,936 subjects (3,894 men and 4,042 women).
From the source population, a random sample was
selected stratifying by sex and survey leading to a subco-
hort of 1,885 participants. After exclusion of subjects with
missing DNA samples and missing values for risk factors,
the final subcohort included 1,687 subjects (910 men,
777 women).
Additionally, all incident type 2 diabetes cases in the
source population were selected, including subjects for
whom the treating physician clearly reported the diagno-
sis or for whom the diagnosis was mentioned in the med-
ical records or who were taking antidiabetic medication.
The number of incident type 2 diabetes cases until Decem-
ber 31st, 2002 was 555 (329 men, 226 women). After
exclusion of subjects with incomplete information on rel-
evant variables, the present study including the subcohort
and incident type 2 diabetes cases, was based on 2,067BMC Medical Genetics 2008, 9:9 http://www.biomedcentral.com/1471-2350/9/9
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participants (307 men, 191 women with incident type 2
diabetes; 835 men, 734 women without incident type 2
diabetes). Mean follow-up time (± SD) was 10.1 (± 4.9)
years. The final stratum-specific sample sizes of this sub-
cohort were used together with the stratum-specific sizes
of the source population to compute sampling fractions,
and the inverse of the sampling fractions yielded survey-
and sex-specific sampling weights.
All cross-sectional analyses concerning SNP frequencies
and tests for departures from Hardy-Weinberg-equilib-
rium were performed in a random sample of the whole
study population with available DNA (i.e. without prior
to exclusion of subjects without follow-up information,
prevalent diabetes, etc.). This sample included 1,968 sub-
jects (1,069 men, 899 women).
Selection and genotyping of polymorphisms
For the SNP selection, the National Center for Biotechnol-
ogy Information SNP database dbSNP Build 124 was used
[21]. SNPs were chosen on the basis of density, frequency
and occurrence in or near functional regions like exons
and hypothetical promoter regions and hypothetical tran-
scription factor-binding sites. In addition, all up to then
known haplotype tagging SNPs were taken into account.
PCR primers were designed by Sequenom's MassArrayAs-
sayDesign program. Genotyping analyses were carried out
by means of matrix-assisted laser desorption ionization-
time of flight analysis of allele dependent primer exten-
sion products as described elsewhere [22]. Genotyping
calls were made in real time with MassArray RT software
(Sequenom, San Diego, USA). Negative controls were
included in all assays. To control for reproducibility of
genotyping data, 12.5% of randomly selected samples
were genotyped in duplicate. The discordance rate was
0.3%. Each SNP was tested for departures from Hardy-
Weinberg-equilibrium by means of a chi-square test or
Fisher's exact test depending on allele frequency.
Assessment of demographic, lifestyle and clinical 
characteristics
Standardized interviews were conducted by trained medi-
cal staff (mainly nurses) to assess information concerning
sociodemographic variables, smoking habits, leisure time
physical activity level and alcohol consumption. In addi-
tion, participants underwent a standardized medical
examination and a nonfasting venous blood sample was
obtained. Detailed information on all survey methods has
been described elsewhere in detail [23]. TC and HDL-C
were measured by enzymatic methods (CHOD-PAP, Boe-
hringer Mannheim, Germany). HDL-C was precipitated
with phosphotungstic acid and magnesium ions.
Statistical analysis
Means or proportions for baseline demographic and clin-
ical characteristics were computed using the SAS proce-
dures SURVEYREG or SURVEYFREQ which estimate
standard errors appropriate to the sampling scheme. Tests
of differences between subjects with and without incident
type 2 diabetes were based on these procedures. In case of
non-normality, tests were carried out with log-trans-
formed variables and results were presented as geometric
means with antilogs of standard errors of the log means.
Cox proportional hazards regression analysis was used to
assess the association between polymorphisms within the
TLR4 gene and incident type 2 diabetes. Due to the case-
cohort design, standard errors were corrected using a
"sampling weight" approach developed by Barlow (1994)
[24]. Since sex-related differences seem to play a role in
the development of diabetes [23,25], all analyses were
done separately for men and women and carried out for
each  TLR4  SNP with a multivariate-adjusted model
including age, body mass index (BMI), systolic blood
pressure (SBP), TC/HDL-C, as well as the categorical vari-
ables survey, smoking status (never smoker, former
smoker, current smoker), alcohol consumption (men 0,
0.1–39.9, ≥ 40 g/d; women 0, 0.1–19.9, ≥ 20 g/d) and
physical activity (inactive vs. active, i.e. regular physical
activity of ≥1 hour/week in both summer and winter).
This model was respectively notated as "main effect
model". To assess whether the impact of TLR4 variants on
incident type 2 diabetes was modified by cholesterol lev-
els, interaction terms of TLR4  variants and TC/HDL-C
were additionally included to the main effect model
("interaction effect model"). Hazard ratios are presented
with their 95% confidence intervals. P-values are based on
robust variance estimates using the Barlow approach.
As measures for pairwise linkage disequilibrium (LD)
between each pair of SNP loci, Lewontin's disequilibrium
coefficient D' and the squared correlation coefficient were
calculated. Haplotype reconstruction was performed
within blocks of high D' using the expectation-maximiza-
tion algorithm haplo.em [26]. To avoid large reconstruc-
tion errors resulting from missing data, haplotype
estimation is based only on subjects with complete geno-
type information. Due to the study design, haplotype esti-
mation for analysis of incident type 2 diabetes had to be
performed separately for cases and non-cases. For associa-
tion analysis within the population-based subcohort, no
distinction had to be made for haplotype estimation.
Haplotypes with frequencies <1% were collected into a
separate group of rare haplotypes ("haplo rare"). The
most frequent haplotype was used as the reference cate-
gory. The effect of haplotypes on incident type 2 diabetes
was assessed in an analogous way as for single SNPs. Due
to the continuous coding of the expected number of hap-BMC Medical Genetics 2008, 9:9 http://www.biomedcentral.com/1471-2350/9/9
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lotypes, an additive effect had to be assumed in haplotype
association analysis.
The global significance level of 5% was corrected for the
number of independent tests following the Bonferroni
procedure. The number of independent tests was calcu-
lated as the number of effective loci obtained through
spectral decomposition of the correlation matrix of all
SNPs analyzed [27]. Therefore, the significance level for
single tests was reduced to α = 0.01, corresponding to an
overall significance level of α = 0.05. All statistical analy-
ses were performed using the statistical package SAS Ver-
sion 9.1 (SAS Institute, Cary, NC) and the statistical
analysis software package R, Version 2.4.1 [28].
Results
Basic description of study population
The baseline demographic, clinical and lifestyle character-
istics of the study participants are shown in Table 1. Sub-
jects who developed type 2 diabetes during the follow-up
period (cases) were older, showed a higher BMI, were
more likely to be current or former smokers and were less
active than subjects without onset of type 2 diabetes (non-
cases). Furthermore, cases more frequently reported a his-
tory of myocardial infarction and hypertension, whereas
no significant differences were observed for alcohol con-
sumption between the two groups. As expected, TC and
TC/HDL-C were considerably higher and HDL-C was con-
siderably lower in cases compared to non-cases. Further-
more, cases had higher systolic and diastolic blood
pressure compared to non-cases.
Association of TLR4 variants and haplotypes with type 2 
diabetes in main effect models
Seven SNPs were genotyped in the TLR4 gene with a mean
genotyping success rate of 98.7%. The assay for rs4986790
(Asp299Gly) failed, but it was tagged by rs4986791
(Thr399Ile). The characteristics of all SNPs are summa-
rized in Table 2. The genotype frequencies of the analyzed
SNPs were consistent with Hardy-Weinberg-equilibrium
criteria. For three SNPs (rs4986791, rs7873784 and
rs1927906) the homozygotes for the minor allele were
pooled with the heterozygotes in the association analysis
in order to avoid conclusions from low numbers, espe-
cially as results where analyzed stratified by gender. None
of the SNPs in the TLR4 gene was significantly associated
Table 1: Baseline demographic, lifestyle and clinical characteristics of the study participants during follow-up (n = 2,067). Data are 
weighted percentages for categorical variables and weighted means (standard errors) for normally distributed continuous variables.
Cases (N = 498) Non-cases (N = 1569) p-value*
Demographic
Sex = male [%] 61.7 53.2 <0.001
Age [yrs] 56.0 (0.4) 51.6 (0.3) <0.001
Clinical
Body Mass Index [kg/m2] 30.0 (0.2) 26.7 (0.1) <0.001
Systolic Blood Pressure [mmHg] 142.2 (0.8) 132.7 (0.5) <0.001
Diastolic Blood Pressure [mmHg] 85.3 (0.5) 81.5 (0.3) <0.001
History of actual hypertension [%] 66.5 39.8 <0.001
History of myocardial infarction [%] 5.0 1.9 0.003
Total cholesterol [mg/dl] 247.4 (2.0) 235.9 (1.1) <0.001
HDL cholesterol [mg/dl] 47.9 (0.6) 57.6 (0.4) <0.001
Ratio TC/HDL-C 5.6 (0.1) 4.5 (0.0) <0.001
Lifestyle
Smoking status [%] 0.002
Current smoker 26.9 24.2
Former smoker 33.3 27.2
Never smoker 39.8 48.6
Frequency of exercise [%] <0.001
Inactive 69.1 58.3
Active 30.9 41.7
Alcohol consumption† [%] 0.112
0 g/d 32.1 28.5
0–39.9/0–19.9 g/d 39.4 44.6
≥ 40/20 g/d 28.5 26.9
Survey‡ <0.001
S1 [%] 36.5 28.9
S2 [%] 39.4 36.1
S3 [%] 24.1 35.0
* t-test for continuous variables and chi-square-test for categorical variables; † Men: 0 g/d, 0–39.9 g/d, ≥40 g/d; Women: 0 g/d, 0–19.9 g/d, ≥20 g/d; ‡ 
Independent cross-sectional studyBMC Medical Genetics 2008, 9:9 http://www.biomedcentral.com/1471-2350/9/9
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with incident type 2 diabetes in multivariate-adjusted
models including age, BMI, SBP, TC/HDL-C, survey,
smoking status, alcohol consumption and physical activ-
ity.
The LD structure across the TLR4 loci is shown in Figure 1.
The strength of LD was reflected by restricted haplotype
diversity. Three major haplotypes were observed with fre-
quencies ranging from 13% to 41% (Table 3). The haplo-
type H1 carrying the major allele at all loci was used as the
reference category. Similar to the analysis of the single
SNPs, none of the haplotypes was associated with
increased risk of incident type 2 diabetes.
Association of TLR4 variants and haplotypes with type 2 
diabetes in interaction effect models
The effect of TLR4 SNPs on incident type 2 diabetes was
modified by TC/HDL-C in men. Five out of seven TLR4
variants showed significant interaction with TC/HDL-C
with p values < 0.018 (test with two degrees of freedom).
Four of them remained significant after correction for
multiple testing (p < 0.01). In women, no significant
effect modification by TC/HDL-C was observed. Hazard
ratios of incident type 2 diabetes for each SNP related to
the respective TC/HDL-C concentration are shown in Fig-
ures 2, 3, 4, 5, 6, 7, 8 for men and Figures 9, 10, 11, 12, 13,
14, 15 for women including the p-values for main and
interaction effects above each figure.
Table 2: Description of TLR4 variants genotyped (n = 1,968).
SNP number dbSNP identifier Exchange Genotype frequenciesa Gene location
(1 > 2) 11 12 22
1 rs2770150 T > C 52.6 40.1 7.3 5'Upstream
2 rs6478317 A > G 46.5 42.7 10.8 5'Upstream
3 rs1927911 C > T 57.6 35.7 6.7 Intronic
4 rs2149356 C > A 47.7 42.2 10.1 Intronic, TFBS
5 rs4986791 C > T 88.1 11.6 0.3 Ile399Thr, HMCS
6 rs7873784 G > C 74.2 23.4 2.4 3'Untranslated region
7 rs1927906 A > G 81.3 18 0.8 3'Flanking
aweighted due to the sampling schene; TFBS: Transcription factor binding site; HMCS: human-mouse conserved segments
Structure of the TLR4 gene and pairwise LD D' und r2 plots Figure 1
Structure of the TLR4 gene and pairwise LD D' und r2 plots.
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For rs6478317 (Figure 3), rs1927911 (Figure 4) and
rs2149356 (Figure 5), the hazard ratio of the heterozygote
genotype compared to the homozygote genotype of the
common allele increased with rising TC/HDL-C from
below 1 (TC/HDL-C < 5) to 1.5 or more (TC/HDL-C > 8).
Similar results were observed for rs4986791 (Figure 6)
and rs1927906 (Figure 8) where heterozygotes and
homozygotes for the minor allele were combined. We
conducted several sensitivity analyses to ensure the
observed associations. Further adjustment for lipid lower-
ing drug intake or exclusion of participants with lipid low
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in men for rs6478317 Figure 3
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in men for rs6478317. Dashed lines 
represent subjects who are homozygote for the minor allele, while contin-
uous lines show heterozygotes. Small bars at the x-axis indicate TC/HDL-
C concentrations of patients with at least one copy of the minor allele.
Table 3: Description of TLR4 haplotypes in the randomly drawn 
subcohort (n = 1,968).
Haplotype SNP number Frequency [%]
1234567M e nW o m e n
H 1 TACCCGA 0 . 4 1 0 . 3 9
H 2 CACCCGA 0 . 2 7 0 . 2 8
H3 T G T A C C A 0.13 0.15
H4 T G T A C G A 0.07 0.07
H 5 TGCATGG0 . 0 6 0 . 0 6
H6 T G T A C G G 0.04 0.03
H 7 TGCCCGA 0 . 0 1 0 . 0 1
Rare 0.01 0.01
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in men for rs2770150 Figure 2
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in men for rs2770150. Dashed lines 
represent subjects who are homozygote for the minor allele, while contin-
uous lines show heterozygotes. Small bars at the x-axis indicate TC/HDL-
C concentrations of patients with at least one copy of the minor allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in men for rs1927911 Figure 4
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in men for rs1927911. Dashed lines 
represent subjects who are homozygote for the minor allele, while contin-
uous lines show heterozygotes. Small bars at the x-axis indicate TC/HDL-
C concentrations of patients with at least one copy of the minor allele.BMC Medical Genetics 2008, 9:9 http://www.biomedcentral.com/1471-2350/9/9
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Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in men for rs7873784 Figure 7
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in men for rs7873784. Continuous 
lines represent subjects who are heterozygote or homozygote for the 
minor allele. Small bars at the x-axis indicate TC/HDL-C concentrations of 
patients with at least one copy of the minor allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in men for rs4986791 Figure 6
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in men for rs4986791. Continuous 
lines represent subjects who are heterozygote or homozygote for the 
minor allele. Small bars at the x-axis indicate TC/HDL-C concentrations of 
patients with at least one copy of the minor allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in men for rs2149356 Figure 5
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in men for rs2149356. Dashed lines 
represent subjects who are homozygote for the minor allele, while contin-
uous lines show heterozygotes. Small bars at the x-axis indicate TC/HDL-
C concentrations of patients with at least one copy of the minor allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in men for rs1927906 Figure 8
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in men for rs1927906. Continuous 
lines represent subjects who are heterozygote or homozygote for the 
minor allele. Small bars at the x-axis indicate TC/HDL-C concentrations of 
patients with at least one copy of the minor allele.BMC Medical Genetics 2008, 9:9 http://www.biomedcentral.com/1471-2350/9/9
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Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in women for  rs1927911 Figure 11
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in women for rs1927911. Dashed 
lines represent subjects who are homozygote for the minor allele, while 
continuous lines show heterozygotes. Small bars at the x-axis indicate TC/
HDL-C concentrations of patients with at least one copy of the minor 
allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in women for  rs6478317 Figure 10
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in women for rs6478317. Dashed 
lines represent subjects who are homozygote for the minor allele, while 
continuous lines show heterozygotes. Small bars at the x-axis indicate TC/
HDL-C concentrations of patients with at least one copy of the minor 
allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in women for  rs2770150 Figure 9
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in women for rs2770150. Dashed 
lines represent subjects who are homozygote for the minor allele, while 
continuous lines show heterozygotes. Small bars at the x-axis indicate TC/
HDL-C concentrations of patients with at least one copy of the minor 
allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in women for  rs2149356 Figure 12
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in women for rs2149356. Dashed 
lines represent subjects who are homozygote for the minor allele, while 
continuous lines show heterozygotes. Small bars at the x-axis indicate TC/
HDL-C concentrations of patients with at least one copy of the minor 
allele.BMC Medical Genetics 2008, 9:9 http://www.biomedcentral.com/1471-2350/9/9
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ering drug intake revealed very similar results. When ana-
lysing interactions excluding subjects with extreme TC/
HDL-C values (below or above one percent of the distri-
bution), the effect modifications remained but did not
reach the level of statistical significance. The findings of
the single SNP analysis were supported by the haplotype
analysis shown in Table 4. In men, the effect of TLR4 hap-
lotypes H5 and H7 on incident type 2 diabetes was mod-
ified by TC/HDL-C. Additionally, borderline significance
was obtained for H4 in men and for H2, H3 and H4 in
women. However, none of the TLR4 SNPs or haplotypes
was associated with TC/HDL-C concentrations in the ran-
domly drawn subcohort neither in men nor in women.
In order to investigate the role of sex-specific differences
and to verify that our findings are not artefacts resulting
from stratified analysis, we also estimated models includ-
ing three-way interaction terms between sex, TC/HDL-C
and the genetic variants. These additional analyses gave
evidence not only for presence of sex-specific differences
of the influence of TC/HDL-C but also modification of
genetic effects by sex, TC/HDL-C as well as sex-specific TC/
HDL-C. For detailed results of the three-way interaction
haplotype model, please see Additional file 1.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in women for  rs1927906 Figure 15
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in women for rs1927906. Continu-
ous lines represent subjects who are heterozygote or homozygote for the 
minor allele. Small bars at the x-axis indicate TC/HDL-C concentrations of 
patients with at least one copy of the minor allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in women for  rs7873784 Figure 14
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in women for rs7873784. Continu-
ous lines represent subjects who are heterozygote or homozygote for the 
minor allele. Small bars at the x-axis indicate TC/HDL-C concentrations of 
patients with at least one copy of the minor allele.
Hazard ratios of incident type 2 diabetes related to the  respective TC/HDL-C concentration in women for  rs4986791 Figure 13
Hazard ratios of incident type 2 diabetes related to the respec-
tive TC/HDL-C concentration in women for rs4986791. Continu-
ous lines represent subjects who are heterozygote or homozygote for the 
minor allele. Small bars at the x-axis indicate TC/HDL-C concentrations of 
patients with at least one copy of the minor allele.BMC Medical Genetics 2008, 9:9 http://www.biomedcentral.com/1471-2350/9/9
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Discussion
To the best of our knowledge, this is the first prospective
study to systematically investigate the association
between genetic variants in the gene coding for the TLR4
receptor and type 2 diabetes using a case-cohort design. In
men the effects of TLR4 SNPs and haplotypes on incident
type 2 diabetes were modified by TC/HDL-C concentra-
tions. However, no effect was seen in women and none of
the investigated SNPs or haplotypes was associated with
type 2 diabetes alone.
Association of TLR4 variants and haplotypes with type 2 
diabetes in main effect models
There was no association between TLR4 SNPs or haplo-
types and type 2 diabetes in our prospective population-
based case-cohort study in main effect models.
Only few epidemiological studies have investigated the
association of TLR4 polymorphisms with type 2 diabetes
focusing only on the two classical polymorphisms
Asp299Gly and Thr399Ile. We recently reported on the
lack of an association between 299Gly and 3399Ile and
prevalent type 2 diabetes or parameters of the metabolic
syndrome using a cross-sectional approach [29]. A study
in patients undergoing coronary angiography, found
299Gly carriage to be associated with a lower prevalence
of diabetes [30]. However, this study represented a case-
only study and did not distinguish between type 1 and
type 2 diabetes. Additionally, carriers of the minor alleles
of these two polymorphisms were associated with reduced
prevalence of diabetic neuropathy in a sample of type 2
diabetes patients [31].
Evidence for a role of TLR4 in type 2 diabetes came from
in-vitro studies. Levels of TLR4 have been reported to be
consistently elevated in the diabetic NZL mouse model.
Furthermore, dysregulated TLR4 mRNA expression corre-
lates with high pro-inflammatory cytokine mRNA and
low IL-10 levels after lipopolysaccharide stimulation [32].
During adipocyte differentiation, mRNA levels of TLR4
are remarkably enhanced in fat tissue of obese mice. Addi-
tionally, TLR4 activation provoked insulin resistance in
adipocytes, suggesting that activation of TLR4 in adi-
pocytes might be implicated in the onset of insulin resist-
ance in obesity and type 2 diabetes [33].
Association of TLR4 polymorphisms and haplotypes with 
incident type 2 diabetes modified by TC/HDL-C
In the present study, the effect of TLR4 SNPs on incident
type 2 diabetes was modified by TC/HDL-C in men, but
not in women. To our knowledge, this effect has not been
described before. An influence of the minor alleles of four
TLR4 variants on the incidence of type 2 diabetes was
observed particularly for patients with high levels of TC/
HDL-C and these findings were supported by haplotype
analysis. In men, two haplotypes H5 and H7 showed a
significant interaction with TC/HDL-C on the risk of inci-
dent type 2 diabetes. H5, the haplotype showing the
strongest effect is tagged by the rare allele of the common
Thr399Ile polymorphism.
The effect of Asp299Gly and Thr399Ile on coronary artery
disease was evaluated in a randomized cholesterol-lower-
ing trial. The authors reported a significant interaction
between genotype and statin treatment in reducing the
risk of clinical cardiovascular events. Furthermore, like in
our sample, they did not observe an effect on lipid param-
eters alone [34].
Several in-vitro and animal studies have focused on the
possible activation of the TLR pathways by hyperlipi-
demia. Oxidized LDL induces upregulation of TLR4
Table 4: Results of haplotype association analysis for type 2 diabetes in interaction effect models (n = 1,968).
Men Women
HR [95% CI] p-value HR [95% CI] p-value
TC/HDL-C 1.02 [0.90; 1.15] 0.74 1.95 [1.55; 2.45] 1.2 × 10-8
H2 0.77 [0.36, 1.65] 0.5 3.11 [1.07; 9.00] 0.04
H3 1.04 [0.55; 1.96] 0.89 4.41 [1.37; 14.21] 0.01
H4 0.29 [0.08; 1.02] 0.05 4.01 [0.99; 16.17] 0.05
H5 0.11 [0.03; 0.45] 1.9 × 10-3 1.47 [0.34; 6.40] 0.61
H6 0.45 [0.11; 1.73] 0.24 0.29 [0.01; 6.73] 0.44
H7 0.05 [0.00; 0.52] 0.01 0.41 [0.02; 10.33] 0.59
TC/HDL-C × H2 1.08 [0.95; 1,24] 0.22 0.76 [0.61; 0.96] 0.02
TC/HDL-C × H3 1.01 [0.92; 1.10] 0.9 0.70 [0.54; 0.91] 0.01
TC/HDL-C × H4 1.28 [1.03; 1.58] 0.02 0.68 [0.51; 0.89] 0.01
TC/HDL-C × H5 1.51 [1.23; 1.87] 1.1 × 10-4 0.95 [0.70; 1.29] 0.74
TC/HDL-C × H6 1.14 [0.95; 1.37] 0.15 1.17 [0.65; 2.08] 0.61
TC/HDL-C × H7 1.63 [1.26; 2.12] 2.1 × 10-4 1.15 [0.64; 2.07] 0.64BMC Medical Genetics 2008, 9:9 http://www.biomedcentral.com/1471-2350/9/9
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expression in macrophages in vitro and might therefore
contribute to the TLR4-dependent inflammatory process
in the arterial wall [10]. An in-vitro study revealed a mech-
anism by which activation of TLR4 results in a strong inhi-
bition of cholesterol efflux from macrophages [35].
Additionally, mouse models of hyperlipidemia have sug-
gested a role for the TLR signaling pathways in hyperlipi-
demia-induced atherosclerosis [36].
Limitations and strengths of the present study
We studied a large cohort of middle-aged men and
women of German nationality. Therefore replication in
other populations is needed before results can be general-
ized. Strengths of the study include a population-based
prospective study design with a long follow-up and the
detailed systematic selection of polymorphisms using LD
information available in public databases and the recon-
struction of haplotypes.
Conclusion
We conclude that minor alleles of several TLR4 variants,
although not directly associated with type 2 diabetes
might increase the risk for type 2 diabetes in subjects with
high TC/HDL-C. Our results confirm previous studies
reporting sex-related dissimilarities in the development of
type 2 diabetes. However, further studies are needed to
replicate these results and analyse the underlying mecha-
nisms.
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